ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
59 announcements with these filters
Alembic Pharmaceuticals has scheduled a board meeting on August 4, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Alembic Pharmaceuticals' partner NATCO Pharma received USFDA tentative approval for Olaparib tablets (100mg and 150mg). Alembic will distribute the product in the U.S. market.
Alembic Pharmaceuticals received a USFDA Warning Letter regarding Informed Consent Form observations at its Vadodara facility. No operational restrictions or material financial impacts are expected.
Alembic Pharmaceuticals fixed July 29, 2026, as the record date for dividend entitlement. Payments will commence on August 6, 2026, subject to shareholder approval.
Alembic Pharmaceuticals submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report includes a Reasonable Assurance Report provided by Bureau Veritas.
Alembic Pharmaceuticals submitted its Integrated Annual Report for FY 2025-26. The report includes the notice for the upcoming Annual General Meeting.
Alembic Pharmaceuticals issued a notice for its 16th AGM on August 5, 2026. Agenda includes dividend declaration and appointment of an Independent Director.
CRISIL has reaffirmed ratings for Alembic Pharmaceuticals. The ratings cover bank loans and commercial papers totaling ₹2,200 Crore.
Alembic Pharmaceuticals received USFDA final approval for Dapsone Gel, 5%. This marks the company's 224th final ANDA approval.
Alembic Pharmaceuticals received USFDA final approval for Oseltamivir Phosphate Oral Suspension. The product has an estimated market size of ₹253.8 Crore.
Alembic Pharmaceuticals redeemed its Commercial Papers of Rs. 150 Crores on the maturity date. This confirms timely debt repayment, reducing outstanding liabilities.
CARE Ratings reaffirmed Alembic Pharmaceuticals' Commercial Paper rating at CARE A1+. The reaffirmation reflects stable credit quality and no change in outlook.
Alembic Pharmaceuticals Limited redeemed Commercial Papers worth ₹100 Crore on their maturity date. This redemption reduces the company's short-term debt obligations and interest burden.
Alembic Pharmaceuticals executed a Shareholders' Agreement to acquire a 45% stake in a new Canadian corporation. The venture focuses on pharmaceutical commercialization in Canada.
Alembic Pharmaceuticals requested physical shareholders to update KYC and nomination details with MUFG Intime India. Compliance ensures timely dividend credits and prevents withholding per SEBI regulations.
Alembic Pharmaceuticals received final USFDA approval for Haloperidol Tablets used in treating psychotic and Tourette’s disorders. This strengthens the company's generic portfolio in the US market.
Alembic Pharmaceuticals announced record dates for the maturity of Commercial Papers totaling ₹250 Crore. This disclosure confirms upcoming debt repayments and maintains financial transparency.
Alembic Pharmaceuticals announced that Atul Suri and Prag Goel ceased being Senior Management Personnel following an internal reporting restructure. This administrative shift streamlines the company's India business reporting.
Alembic Pharmaceuticals appointed Mr. Ramesh Juneja as Executive Vice President and Senior Management Personnel. He brings three decades of pharmaceutical sales and marketing experience.
Alembic Pharmaceuticals successfully redeemed Commercial Papers worth ₹150 Crore on their maturity date of May 29, 2026. This reflects disciplined debt management and liquidity.
Alembic Pharmaceuticals received USFDA final approval for Levothyroxine Sodium Tablets USP. The market size is estimated at ₹17942.4 Crore, strengthening the company's US generic portfolio.
Alembic Pharma delivered Q4 FY26 revenue of ₹1,838 Cr (up 4% YoY) and PAT of ₹203 Cr. FY26 revenue grew 10% YoY to ₹6,201 Cr with 25% EBITDA margins before R&D.
Management showcases a 100-year legacy transitioning into a high-tech global pharmaceutical player through massive facility expansion and R&D focus.
Alembic Pharma reported Q4FY26 revenue of INR 18.48 Bn, up 4% YoY, and PAT of INR 2.03 Bn, up 29% YoY. The company launched its first branded product, Pivya, in the US.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹1,848 Cr (+4.4% YoY) and net profit of ₹202.7 Cr (+29.2% YoY) for Q4 FY26.
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹1,848 Cr (+4.4% YoY) and net profit of ₹201.5 Cr (+28.7% YoY) for Q4 FY26.
Mr. Rohit Garg resigned as Senior Vice President at Alembic Pharmaceuticals effective May 14, 2026. His departure for personal reasons marks a change in senior management.
Alembic Pharmaceuticals received an Establishment Inspection Report from the USFDA for its Karakhadi injectable facility. The successful inspection conclusion supports continued operational compliance at the site.
Alembic Pharmaceuticals received USFDA tentative approval for Darolutamide Tablets, targeting a ₹29,972.5 Crore market. This approval strengthens the company's oncology portfolio and international growth prospects.